According to the Zhiyu Finance APP, China International Capital Corporation released a research report stating that it has raised the Target Price of PEIJIA-B (09996) by 25% to 5 Hong Kong dollars, while maintaining an "outperform the Industry" rating. China International Capital Corporation noted that since the second half of 2024, the company's valve Business has maintained a good growth trend; multiple procurement for Neurointervention has been occurring.

The report mentioned that TAVR implant volumes are expected to grow by 35-40% throughout 2024. The company's Neurointervention remains in a healthy state, as domestic alternatives have arrived. It is anticipated that Neurointervention revenue will increase by 35-40% year-on-year to approximately 0.35 billion yuan, with rapid growth in products like spring coils, thrombectomy Brackets, micro guidewires, and balloon dilation catheters.

Additionally, according to monthly tracking and calculations, it is expected that the total number of TAVR (transcatheter aortic valve replacement) surgeries in 2024 may reach 3,400-3,500, representing a year-on-year growth of 35-40%, which generally meets expectations. The company's rich product matrix will help respond to subsequent changes in the competitive landscape, allowing the company to continue maintaining its position as a leading enterprise in the valve market.